Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
|Articles|February 25, 2013
Mini-quiz: Major Depressive Disorder
Major depression is a common chronic illness within the general US population. What is the approximate prevalence for MDD in the US population?
Advertisement
Major depression is a common chronic illness within the general US population. How common? Take the quiz, learn more.
For the answer,
Answer:c
Major depression is a common chronic illness within the general US population, with a prevalence of approximately 5% to 10%.
For more on this topic, please see
Advertisement
Related to this article
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Cannabis Use Prevalent In Substance-Related Adolescent Emergency Care: Insights From Kevin Xu, MD
2
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
3
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
4
Promoting Literacy to Improve Child Development: Reading Model Boosts Efforts
5